Phospholamban inhibits Ca-ATPase conformational changes involving the E2 intermediate.

Area of Science:

• Biochemistry
• Molecular Biology
• Cardiovascular Science

Background:

• Phospholamban (PLB) is a key regulator of cardiac sarcoplasmic reticulum Ca2+-ATPase (SERCA2a).
• Understanding PLB's precise interaction with SERCA2a is crucial for cardiac function.
• Previous studies suggest PLB stabilizes SERCA2a in the E2 state.

Purpose of the Study:

• To investigate the hypothesis that phospholamban (PLB) stabilizes the Ca-ATPase (SERCA2a) in the E2 intermediate state.
• To elucidate the conformational effects of PLB binding on SERCA2a using biophysical and enzymatic methods.

Main Methods:

• Expression and isolation of SERCA2a alone and co-expressed with PLB in insect cells.
• Steady-state fluorescence spectroscopy of Ca-ATPase labeled with NBD-MPE.
• Enzyme kinetic assays, including Ca2+ dependence, inorganic phosphate (Pi) phosphorylation, and vanadate inhibition.

Main Results:

• PLB binding decreased the amplitude of the SERCA2a E2 to E1 conformational transition by 45% and shifted Ca2+ dependence to higher levels.
• PLB reduced the amplitude of Ca-ATPase phosphorylation by Pi by 55% and slightly decreased Pi affinity.
• PLB decreased SERCA2a sensitivity to vanadate, indicating stabilization of a non-E2 conformation.

Conclusions:

• PLB binding to SERCA2a stabilizes a conformation distinct from the E2 state.
• This stabilization reduces the enzyme's capacity for E2-mediated conformational changes.
• The E2-like state induced by PLB is not in simple equilibrium with E1 or E2 states.